# US 2008/0187550 A1 · Immunomodulatory Peptides Derived from Heat Shock Proteins and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187550 A1
- Document ID: US20080187550A1
- Status: Published application
- Kind: A1
- Application number: 11/938,762
- Filed: 2007-11-12
- Published: 2008-08-07
- Earliest claimed: 2000-11-01
- Inventors: Salvatore Albani; Dennis A. Carson; Berent J. Prakken; Alberto Martini
- Web page: https://patentgrep.com/patent/US20080187550A1

## CPC

- C07K 14/195: from bacteria
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4702: {Regulators; Modulating activity}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method of modulating an immune response in a subject is disclosed. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the inflammation-related symptoms of an immune-mediated disease, such as arthritis, can be achieved by modulation of the underlying immune response itself, rather than by merely addressing the resulting inflammation. This strategy can be used to regulate the inflammatory response and is applicable to a variety of contexts in which immune modulation is desired, such as mucosal tolerization, DNA vaccination, anergy induction, active immunization, and ex vivo modulation of antigen-specific T cells. In one embodiment, the method comprises administering to the subject a bacterial dnaJ peptide or a human homolog or a non-homologous human isoform thereof.

## Claims

### Claim 1

A method of modulating an immune response in a subject, the method comprising administering an immunogenic peptide portion of a dnaJ heat shock protein (hsp) to the subject, thereby modulating an immune response in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dnaJ hsp is a bacterial dnaJ hsp.

### Claim at position 3

3-65. (canceled)

### Claim 66 (depends on 1)

The method of claim 1, wherein the dnaJ hsp is a human dnaJ hsp.

### Claim 67 (depends on 1)

The method of claim 1, wherein the peptide is selected from the group consisting of SEQ ID NOs: 1 to 18, 20 to 26, and any combination thereof.

### Claim 68 (depends on 1)

The method of claim 1, wherein the peptide is SEQ ID NO: 19 in combination with any one or more of SEQ ID NOs: 1 to 18, 20 to 26.

### Claim 69 (depends on 1)

The method of claim 1, wherein the peptide is administered intradermally, subcutaneously, intramuscularly, or mucosally.

### Claim 70 (depends on 1)

The method of claim 1, wherein the subject has an immunological disorder.

### Claim 71 (depends on 70)

The method of claim 70, wherein the immunological disorder is an arthritis.

### Claim 72 (depends on 71)

The method of claim 71, wherein the arthritis is articular juvenile idiopathic arthritis.

### Claim 73

A method of modulating immunoeffector cell responsiveness, the method comprising contacting immunoeffector cells with a peptide portion of a dnaJ heat shock protein (hsp) to the subject.

### Claim 74 (depends on 73)

The method of claim 73, wherein the peptide is selected from the group consisting of SEQ ID NOs: 1 to 18, 20 to 26, and any combination thereof.

### Claim 75 (depends on 73)

The method of claim 73, wherein the peptide is SEQ ID NO: 19 in combination with any one or more of SEQ ID NOs: 1 to 18, 20 to 26.

### Claim 76 (depends on 73)

The method of claim 73, wherein contacting the immunoeffector cells comprises administering the peptide to a subject, wherein said contacting occurs in vivo.

### Claim 77 (depends on 73)

The method of claim 73, wherein contacting the immunoeffector cells is performed in vitro.

### Claim 78 (depends on 73)

The method of claim 73, further comprising administering the immunoeffector cells to a subject, thereby modulating an immune response in the subject.

### Claim 79 (depends on 78)

The method of claim 78, wherein the immunoeffector cells are autologous with respect to the subject.

### Claim 80 (depends on 78)

The method of claim 78, wherein the immunoeffector cells are allogeneic with respect to the subject.

### Claim 81 (depends on 73)

The method of claim 73, wherein the immunoeffector cells are T cells.

### Claim 82 (depends on 73)

The method of claim 73, further comprising contacting the immunoeffector cells with an immunoadjuvant.

### Claim 83 (depends on 82)

The method of claim 82, wherein the immunoadjuvant is a cytokine.
